Leadership
Recent moves in the industry include changes at the top at Odyssey Therapeutics and Taiho Oncology, plus Ocular Therapeutix gets a new global chief commercial officer from Merck.
Scrip spoke with Novo’s SVPs for global research and global business development, Jacob Petersen and Tamara Darsow, about dealmaking and R&D priorities after the company streamlined to focus more intensely on obesity and diabetes.
Paul Hudson has acknowledged the firm’s R&D setbacks but says they are par for the course when tackling science ‘that has never been done before.’
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip. After extensive coverage of the Annual JPM Healthcare Conference in San Francisco, we also highlight some of the insightful and memorable quotes across the week.
Revenue from Sun Pharma’s innovative medicines business overtook its generics business for the first time ever in Q2 of fiscal year 2026 and North American CEO Richard Ascroft is focused on maintaining the growth momentum.
Obesity drug MariTide and olpasiran in cardiovascular disease will not produce Phase III data until 2027, but Scrip spoke with Amgen EVP of R&D James Bradner about those programs, near-term pivotal readouts and dealmaking to boost research capabilities.
Fund IV exclusively targets company creation and early-stage investing across the UK and the US.
The company is getting ready for multiple cancer drug launches, potentially including anti-PD-L1/VEGF pumitamig. Chief commercial officer Annemarie Hanekamp spoke to Scrip.
The company’s chief operating officer and next CEO Karen Massey talked with Scrip about the rise of Vyvgart and how the Dutch biotech is planning for the next phase of growth.
The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.
Recent moves in the industry include changes at the top at Oncolytics Biotech and internal moves at Zymeworks, plus Circurna gets a new chief scientific officer from Pfizer.
The pharma titan candidly speaks about the M&A landscape, high R&D costs and the potential of AI as the industry gets set to navigate a host of existing and new challenges.
Biogen’s president and head of North America talked to Scrip about the company’s commercial expansion into new areas in immunology and nephrology.
Recent moves in the industry include C-suite changes at Compass Therapeutics, Galecto and Archeus Technologies, plus Chordia Therapeutics gets a new CMO from Merck.
Europe produces world-class science, but lags behind other regions in translating discoveries into groundbreaking innovations that create jobs and drive economic growth. A new fund from the owners of Novo Nordisk hopes to change that.
The CEO of Inno Medicine tells Scrip the Chinese company has developed a novel active-targeting nano-liposomal formulation to reverse coronary atherosclerosis plaque, which has yielded positive proof-of-concept Phase Ib/IIa results.
An uptick in deals, venture financings and biopharma stock prices could set a boisterous mood for the pharmaceutical industry’s annual business meeting in San Francisco.
Recent moves in the industry include new VP appointments at Evogene and Evotec, plus Yiling Pharmaceutical gets a new COO from Sanofi.
Servier has deepened its AI-enabled collaborations with a deal potentially worth over €1bn with Iktos to accelerate small-molecule drug discovery for undisclosed targets in oncology and neurology.
The recent Evaluate Financing Forum saw three high-calibre panellists give real-world insight into the best ways to secure the best partnerships.